Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma

Journal of Clinical Oncology

Volumn 32, Issue 17, 2014, Pages 1776-1781

  Kobe, Carsten ^a   Kuhnert, Georg ^a   Kahraman, Deniz ^a   Haverkamp, Heinz ^a   Eich, Hans Theodor ^a,b   Franke, Mareike ^a   Persigehl, Thorsten ^a   Klutmann, Susanne ^c   Amthauer, Holger ^d   Bockisch, Andreas ^e   Kluge, Regine ^f   Wolf, Hans Heinrich ^g   Maintz, David ^a   Fuchs, Michael ^a   Borchmann, Peter ^a   Diehl, Volker ^a   Drzezga, Alexander ^a   Engert, Andreas ^a   Dietlein, Markus ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROCARBAZINE; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; VINCRISTINE; YOUNG ADULT;

EID: 84905860735     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.2507     Document Type: Article

References (23)

1. Diehl V, Mauch PM, Harris NL: Hodgkin's disease, in DeVita VT, Hellmann S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 6). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 2339-2387
2. Friedberg JW: Hodgkin lymphoma: Answers take time! Blood 117:5274-5276, 2011
3. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 (Pubitemid 36682817)
4. Engert A, Haverkamp H, Kobe C, et al: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791-1799, 2012
5. Markova J, Kahraman D, Kobe C, et al: Role of [18F]-fluoro-2-deoxy-D- glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma 53:64-70, 2012
6. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007 (Pubitemid 47372616)
7. Schaefer NG, Taverna C, Strobel K, et al: Hodgkin disease: Diagnostic value of FDG PET/CT after first-line therapy: Is biopsy of FDG-avid lesions still needed? Radiology 244:257-262, 2007 (Pubitemid 46981981)
8. Dann EJ, Bar-Shalom R, Tamir A, et al: Riskadapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109:905-909, 2007 (Pubitemid 46220633)
9. Juweid ME, Stroobants S, Hoekstra OS, et al: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007 (Pubitemid 350002965)
10. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
11. Hung H, Chiang C: Estimation methods for time-dependent AUC with survival data. Can J Stat 38:8-26, 2010
12. Hoppe RT, Advani RH, Ai WZ, et al: Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:589-597, 2012
13. Biggi A, Gallamini A, Chauvie S, et al: International validation study for interim PET in ABVD-treated, advanced stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med 54:683-690, 2013
14. Furth C, Meseck RM, Steffen IG, et al: SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: Is there a benefit for PPV in early response assessment by FDG-PET? Pediatr Blood Cancer 59:475-480, 2012
15. Kahraman D, Scheffler M, Zander T, et al: Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med 52:1871-1877, 2011
16. Kobe C, Scheffler M, Holstein A, et al: Predictive value of early and late residual 18Ffluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging 39:1117-1127, 2012
17. Tseng D, Rachakonda LP, Su Z, et al: Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease. Radiat Oncol 7:5, 2012
18. Kahraman D, Holstein A, Scheffler M, et al: Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med 37:1058-1064, 2012
19. Groheux D, Hatt M, Hindié E, et al: Estrogen receptor-positive/ human epidermal growth factor receptor 2-negative breast tumors: Early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer 119:1960-1968, 2013
20. Boellaard R: Need for standardization of 18FFDG PET/CT for treatment response assessments. J Nucl Med 52: 93S-100S, 2011
21. Meignan M, Gallamini A, Haioun C: Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257-1260, 2009
22. Kostakoglu L, Gallamini A: Interim 18F-FDG PET in Hodgkin lymphoma: Would PET-adapted trials lead to paradigm shift? J Nucl Med 54:1082-1093, 2013
23. Meignan M, Barrington S, Itti E, et al: Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 55:31-37, 2014